A $365 billion industry is holding the world's food and medicine together — and it's held together with generators, guesswork, and prayers in most of the countries that need it most.
Here is a fact that should unsettle you. Right now, somewhere between Chattogram Port and a pharmacy in Sylhet, a shipment of insulin is sitting in an unrefrigerated van. The driver doesn't know — or perhaps he does and has no alternative. The patient waiting at the other end has no idea. And the healthcare system logging the delivery will record it as a successful transfer.
This is not a hypothetical. This is the last mile of the cold chain, playing out every single day across South Asia, Sub-Saharan Africa, and dozens of other fast-growing markets that global investors are rushing to enter — while simultaneously underinvesting in the foundational infrastructure those markets require.
The cold chain — the network of temperature-controlled storage, refrigerated transport, and real-time monitoring that keeps perishable goods alive between production and consumption — is one of the least glamorous and most consequential industries on earth. While the world talks about AI, fintech, and the creator economy, a $365 billion industrial sector is quietly determining whether your food is safe, whether your medicine works, and whether the next pandemic response collapses at the warehouse door.
It is also, by almost every measure, catastrophically underdeveloped in the markets that need it most.
The Invisible Infrastructure Nobody Wants to Fund
When people talk about infrastructure investment in emerging markets, they mean roads, ports, and broadband. Cold chain infrastructure — refrigerated warehouses, reefer fleets, temperature-monitoring networks — rarely makes the headline list. It is unsexy. It is capital-intensive. The returns are slow. And yet, without it, everything else begins to fail in ways that are quiet, dispersed, and almost impossible to trace back to their root cause.
Consider what the cold chain actually does. It maintains what the industry calls thermal integrity — an unbroken temperature window from the point of production or manufacture to the point of consumption. For most pharmaceuticals, that window is 2–8°C. Deviate by two degrees for two hours, and a vaccine that cost $12 to manufacture and $4 to ship is worth nothing. Not slightly less. Nothing. There is no partial credit in the cold chain.
For food — fresh produce, seafood, dairy, meat — the arithmetic is equally brutal. The FAO estimates that roughly one-third of all food produced globally is lost or wasted every year. In developing countries, 40% of that loss happens at the post-harvest and processing stages — precisely where cold chain infrastructure is weakest. In Bangladesh specifically, post-harvest losses run between 30–40%, driven almost entirely by the absence of cold storage between farm and market.
"Reducing food loss is not an agricultural problem. It is a logistics problem with agricultural consequences." — Adapted from FAO post-harvest loss analysis framework
The economic cost of this is staggering. Globally, food valued at an estimated $400 billion is lost between harvest and retail every year, according to FAO data. That figure does not include pharmaceutical waste, which runs into tens of billions more annually. Together, they represent an invisible tax levied on the world's poorest supply chains — paid by farmers who can't get market price, by patients who receive compromised medicine, and by governments whose public health programs quietly underperform their intended efficacy.
The Vaccine Scandal Nobody Is Calling a Scandal
Here is the statistic that stops every supply chain strategist cold. According to WHO-cited data and multiple peer-reviewed reviews, between 25% and 50% of vaccines worldwide are wasted due to cold chain failures — temperature excursions, power outages, improper handling, and last-mile breakdowns that render doses ineffective before they reach the patient.
Read that again. Up to half of the vaccines produced — manufactured at significant cost, distributed at enormous logistical effort, administered by healthcare workers in some of the most resource-constrained settings on earth — may be delivering nothing. And in most cases, neither the patient nor the healthcare worker knows.
This is not a theoretical risk. A global review of vaccine supply across 89 countries found that for most cold chain performance indicators, outcomes fell below the WHO's recommended 80% threshold. Between 19% and 38% of vaccines worldwide are accidentally exposed to freezing temperatures — which can compromise potency just as surely as heat — according to UNICEF monitoring data. COVID-19 exposed the deeper fragility: the ultra-cold requirements for mRNA vaccines (-70°C for Pfizer-BioNTech) revealed that most developing-country health systems had no infrastructure remotely capable of handling next-generation biologics.
Bangladesh: A Case Study in the Infrastructure-Climate Paradox
Bangladesh is an instructive case — not because it represents the worst cold chain failure in the world, but because it represents the most common type: a rapidly growing economy, with expanding pharmaceutical and food export ambitions, sitting on top of a cold chain infrastructure that was designed for a much smaller, less demanding supply chain.
The country faces what analysts call the infrastructure-climate paradox. Bangladesh's geography and climate create extreme demand for cold chain capacity — high ambient temperatures, intense humidity, and a monsoon cycle that degrades unrefrigerated produce within hours. Simultaneously, the same climate conditions put maximum stress on the refrigeration equipment trying to meet that demand. A reefer unit working in 38°C heat and 85% humidity is consuming roughly 30–40% more energy than the same unit operating in a temperate European climate, while facing a higher mechanical failure rate and a shortened service life.
The Load-Shedding Variable
Layer onto this Bangladesh's energy reliability challenge. Load shedding — scheduled and unscheduled power outages — has historically been a structural feature of the national grid, particularly outside Dhaka. For cold storage operators, this means that maintaining a consistent 2–8°C environment requires redundant power systems as standard, not as backup. Generators, solar-assisted cooling arrays, and high-capacity battery banks are not optional extras — they are the operational baseline. This dramatically increases CAPEX for any cold chain investment and creates a significant barrier to entry for smaller operators serving secondary cities and rural areas.
The Last-Mile Collapse
Long-haul cold chain in Bangladesh has been improving. Major operators like Golden Harvest Cold Chain Logistics have expanded refrigerated warehousing capacity in Dhaka and Chattogram to serve growing pharmaceutical and food processing demand. The port infrastructure at Chattogram is developing. The institutional appetite is there.
But the last mile — the final movement from a central cold hub to a local pharmacy, a district hospital, a rural market — remains the system's exposed nerve. Ordinary vans, motorcycles, and hand-carry replace reefer vehicles. A shipment of vaccines that survived a 5,000-mile refrigerated journey from manufacturer to Chattogram can be effectively destroyed in the last 40 kilometres. A crate of fresh hilsa, kept at perfect temperature through a regional distribution hub, arrives at a Sylhet market stall having spent two hours in the back of a non-refrigerated Tata truck.
The last mile is where the cold chain breaks. And in Bangladesh — as in most developing markets — it breaks routinely, invisibly, and with consequences that ripple out into food security, public health, and national economic productivity.
Technology Is Not the Bottleneck. Capital Allocation Is.
Here is where the standard narrative about the cold chain gets the diagnosis wrong. The technology to fix this problem exists. It has existed for a decade. IoT-enabled reefer units can transmit real-time temperature data to a dispatcher in Dhaka from a truck on the Chittagong highway. Two-way telematics allow remote adjustment of temperature setpoints mid-journey. Door sensors calculate heat gain every time cargo is accessed. Digital audit trails provide the GDP and HACCP compliance documentation that pharmaceutical export markets demand.
This technology is not experimental. It is commercially available, increasingly affordable, and actively deployed by leading operators. In April 2025, DHL Group announced a $2.2 billion investment in biopharma cold chain operations globally, with half allocated to the Americas and the remainder split between Asia Pacific, Europe, the Middle East, and Africa. DHL's investment is not a bet on future technology — it is a bet on present demand that existing infrastructure cannot serve.
The gap is not technological. The gap is between the cost structure of deploying this technology at scale in developing markets and the risk appetite of the capital that could finance it.
| Technology | Availability | Real Barrier to Deployment |
|---|---|---|
| IoT real-time temperature monitoring | Commercially available | Connectivity gaps in rural last mile; device cost at scale |
| Two-way reefer telematics | Commercially available | Requires reefer fleet — most last-mile operators use ordinary vans |
| Phase Change Material (PCM) packaging | Commercially available | Unit cost vs. margin structure of local distributors |
| Solar-assisted cold storage | Commercially available | High CAPEX; financing access for small operators |
| Digital GDP/HACCP audit systems | Commercially available | Regulatory enforcement inconsistency; operator training |
| Ultra-cold (-70°C) mRNA vaccine storage | Available, premium cost | Near-zero deployment in LMICs outside capital cities |
This table tells a specific story. Every solution exists. The blockage is economic — a mismatch between the capital intensity of deploying these solutions and the credit availability, margin structures, and risk frameworks that govern investment decisions in emerging markets.
The Business Case: Who Builds This Wins the Decade
The global cold chain market is projected to grow from roughly $365 billion in 2024 to over $1.4 trillion by 2034 — a CAGR of approximately 14.5%, according to Precedence Research. That growth is not evenly distributed. Asia-Pacific is the fastest-growing regional market. India is projected to be the highest CAGR country globally through 2033. Bangladesh, positioned at the intersection of a massive domestic food market and a rapidly expanding pharmaceutical export industry, sits inside that growth curve.
The strategic logic is straightforward. Three converging forces are creating irreversible demand for cold chain infrastructure in South Asia.
1. The Pharmaceutical Export Opportunity
Bangladesh's pharmaceutical sector exports to over 150 countries. Its ambition is to move up the value chain — from generic APIs to biologics, biosimilars, and eventually mRNA-platform products. Every step up that value chain requires colder, more precise, more rigorously monitored supply chains. A country that cannot guarantee 2–8°C integrity across its domestic distribution network will struggle to meet the GDP compliance requirements of regulated export markets in the EU and North America.
2. The Food Export Premium
Bangladesh exports shrimp, hilsa, and vegetables to high-value markets in Europe, the Middle East, and North America. The price premium for cold-chain-certified, traceable, temperature-logged exports over commodity-grade product can be 40–80%. That premium is entirely captured or destroyed at the cold chain layer. Operators who can certify unbroken thermal integrity command fundamentally different price points than those who cannot.
3. The Middle-Class Demand Curve
As household incomes rise, consumer demand shifts toward fresh, chilled, and frozen products — dairy, processed meats, ready meals, imported fruits. This is not a Bangladeshi anomaly; it is a universal pattern at every income level of development. The modern retail and e-commerce grocery channels that serve this rising middle class cannot function without cold chain infrastructure behind them.
What "Winning" Actually Looks Like
The cold chain is not a product. It is not an app. It is not something that scales by downloading it. It is physical infrastructure — warehouses, trucks, generators, sensors, trained technicians, and standard operating procedures — that has to be built, maintained, and staffed in the real physical world, in the actual climate, with the actual power grid.
This makes it hard. It makes it slow. It makes it capital-intensive in a way that frustrates investors trained on software-like return curves. And it makes the barriers to entry genuinely high for the operators who do it properly.
That is precisely why the upside is real. In markets where cold chain integrity is the exception rather than the standard, the operator who can deliver it — and certify it — has a structural competitive advantage that no amount of marketing can replicate. You either kept the vaccine at 4°C from Chattogram to Cox's Bazar, or you didn't. The IoT log either shows an unbroken temperature record, or it doesn't.
The Cold Chain Is the Industrial Frontier — And the Window Is Open Now
The investment thesis is straightforward: the cold chain is growing at 14.5% annually, is structurally underdeveloped in the fastest-growing markets, and is protected by high physical barriers to entry. Here is how to think about it strategically:
- The technology gap is solved. The capital gap is not. For founders and investors, the opportunity is not in inventing cold chain technology — it is in financing and deploying it at scale in markets where institutional capital has been slow to follow demand.
- Pharmaceutical cold chain is the highest-margin vertical. Food cold chain is high volume but thin margin. Pharma is lower volume, higher complexity, and commands premium pricing — particularly for GDP-compliant, audit-ready operations serving export markets.
- Last-mile is the unsolved problem and the largest opportunity. Long-haul cold chain is improving across South Asia. The last mile is where the system fails. The operator who solves last-mile refrigeration at scale — through reefer motorcycles, PCM-insulated boxes, or solar micro-hubs — will own the most defensible market position in the sector.
- PPP structures are the financing model for this decade. The capital intensity of cold chain infrastructure, combined with its public-good characteristics (food security, vaccine distribution), makes it ideally suited to public-private partnership financing. BOT and DBFOT models at port facilities and airport cold hubs are already proving viable in Bangladesh.
- Data is the next cold chain asset. The operator who owns the temperature log, the compliance record, the delivery audit trail — owns a data asset that pharmaceutical companies, insurers, and regulators will pay for. Cold chain is becoming an information business with refrigeration attached.
The Stakes Are Higher Than the Market Size Suggests
There is a tendency, in business writing, to frame every industrial trend as an "opportunity." The cold chain deserves a more honest framing than that.
When a cold chain fails, someone gets sick from spoiled food. A child receives a compromised vaccine and remains vulnerable to a disease that the healthcare system believed it had immunized against. A farmer in Rangpur who grew a perfect crop of tomatoes watches 35% of it rot because there was no cold storage within viable transport distance. A pharmaceutical company loses a $200,000 biological shipment at the Chittagong port because the cross-dock facility ran out of generator fuel.
These are not abstractions. They are the daily, distributed, unrecorded cost of cold chain failure in developing markets — a cost that is borne almost entirely by people with the least capacity to absorb it.
The good news is that this is a solvable problem. The technology exists. The market demand is real and growing. The financing models are available. What has been missing is the combination of strategic clarity, patient capital, and operational seriousness that complex physical infrastructure requires.
Temperature is not a logistics detail. In 2026, it is a strategic variable. The businesses and governments that treat it as such will build something that lasts. The ones that treat it as an afterthought will keep paying the invisible tax — in spoiled goods, in compromised medicine, and in the quiet, preventable failures that never make the headline but shape everything underneath it.
SM Jahed writes about business strategy, industrial trends, and the economics behind global supply chains at meowbhai.blogspot.com.
Data sources: Precedence Research Cold Chain Logistics Market Report (2025); Grand View Research Cold Chain Market (2025); FAO Global Food Losses and Food Waste; World Bank Post-Harvest Loss Data; WHO Vaccine Cold Chain Performance; PMC — Challenges and Innovations of Vaccine Cold Chain Distribution in Developing Countries (2026); PATH Global Immunization Impact Analysis; TBS News — Bangladesh Cold Chain Infrastructure (2023); Wiley — Food Safety in Bangladesh (2025); Trace Data Research Bangladesh Cold Chain Market Report.
Post a Comment